Table 3.
Patient and tumor characteristics by ESR1 gene status including ESR1 gene status in accordance to average values of ESR1/CEN‐6 ratio, ESR1 copy number, CEN‐6 copy number, ER DCC and ER IHC
| Patient and tumor characteristics by ESR1 copy number status | ||||
|---|---|---|---|---|
| Variable | ESR1 Deletion (<0.80) | ESR1 Normal (0.80–<1.30) | ESR1 Gain (1.30–<2.00) | ESR1 Amplification (≥2.00) |
| ESR1 gene status: primary tumor N = 220 (%) | 70 (32%) | 59 (27%) | 41 (19%) | 50 (23%) |
| Average ESR1/CEN‐6 Ratio | 0.60 | 1.10 | 1.57 | 3.96 |
| Average number of ESR1/nucleus | 1.63 | 2.23 | 2.70 | 5.87 |
| Average number of CEN‐6/nucleus | 2.76 | 2.04 | 1.73 | 1.55 |
| Average ER DCC value (fmol/mg protein) | 128 | 158 | 232 | 377 |
| Average percentage of ER IHC positive cells (N = 149) | 25% (51) | 40% (35) | 52% (29) | 58% (34) |
| Lymph node status: (n pos. nodes) | ||||
| 0 | 6 | 9 | 4 | 4 |
| 1–3 | 33 | 37 | 23 | 23 |
| >3 | 28 | 10 | 14 | 22 |
| Unknown | 3 | 3 | 0 | 1 |
| Tumor size (mm) | ||||
| 0–20 | 20 | 7 | 9 | 14 |
| 21–50 | 35 | 38 | 24 | 29 |
| >50 | 15 | 14 | 8 | 7 |
| Histology | ||||
| Ductal carcinoma | 63 | 53 | 39 | 47 |
| Lobular carcinoma | 2 | 4 | 2 | 0 |
| Other | 5 | 2 | 0 | 3 |
| Malignancy grade | ||||
| Grade 1 | 13 | 15 | 6 | 10 |
| Grade 2 | 39 | 30 | 29 | 29 |
| Grade 3 | 15 | 13 | 6 | 9 |
| Unknown | 3 | 1 | 0 | 2 |